Digest Network Come funziona
Network
/
Società
Co
Non verificato

Contineum Therapeutics, Inc.

Di cosa scriviamo

BiotecnologiaFarmaceuticaMedicina - VarieSaluteWeb e Social Network

23 comunicati stampa

Guarda tutti i comunicati
20/11/2025
Industria
Scienza
Medicina - Varie
Biotecnologia
Salute
Farmaceutica
Sanità
Contineum Therapeutics Reports Topline Data From Its Phase 2 PIPE-307 VISTA Trial for the Treatment of Relapsing-Remitting Multiple Sclerosis (RRMS)
Fonte
Contineum Therapeutics, Inc.
Emittente
Business Wire
1.00
0
30/10/2025
Biotecnologia
Salute
Farmaceutica
Medicina - Varie
Mercato azionario
Contineum Therapeutics Reports Third-Quarter 2025 Financial Results; Affirms Key Clinical Development Milestones
Fonte
Contineum Therapeutics, Inc.
Emittente
Business Wire
1.00
0
18/09/2025
Biotecnologia
Salute
Farmaceutica
Medicina - Varie
Industria
Contineum Therapeutics Reports Positive Topline Data From Phase 1b Positron Emission Tomography (PET) Trial of PIPE-791
Fonte
Contineum Therapeutics, Inc.
Emittente
Business Wire
1.00
0
28/08/2025
Salute
Medicina - Varie
Scienza
Farmaceutica
Biotecnologia
Eventi
Web e Social Network
Contineum Therapeutics to Present at September Investor Conferences
Fonte
Contineum Therapeutics, Inc.
Emittente
Business Wire
1.00
0
05/08/2025
Biotecnologia
Salute
Farmaceutica
Medicina - Varie
Mercato azionario
Contineum Therapeutics Reports Second-Quarter 2025 Financial Results; Updates Key Clinical Development Milestones
Fonte
Contineum Therapeutics, Inc.
Emittente
Business Wire
1.00
0
25/06/2025
Salute
Medicina - Varie
Scienza
Farmaceutica
Biotecnologia
Industria
Contineum Therapeutics Provides Update on Phase 1b Positron Emission Tomography (PET) Trial of PIPE-791
Fonte
Contineum Therapeutics, Inc.
Emittente
Business Wire
1.00
0
15/05/2025
Eventi
Web e Social Network
Biotecnologia
Farmaceutica
Salute
Medicina - Varie
Contineum Therapeutics to Present at the 2025 RBC Capital Markets Global Healthcare Conference
Fonte
Contineum Therapeutics, Inc.
Emittente
Business Wire
1.00
0
14/05/2025
Mercato azionario
Biotecnologia
Salute
Farmaceutica
Medicina - Varie
Contineum Therapeutics Reports First-Quarter 2025 Financial Results; Affirms Key Clinical Development Milestones
Fonte
Contineum Therapeutics, Inc.
Emittente
Business Wire
1.00
0
28/04/2025
Mercato del lavoro
Finanza
Mercato azionario
Salute
HIV, AIDS e malattie autoimmuni
Sanità
Farmaceutica
Biotecnologia
Contineum Therapeutics Appoints Timothy Watkins, M.D., M.Sc., as Chief Medical Officer and Head of Development
Fonte
Contineum Therapeutics, Inc.
Emittente
Business Wire
1.00
0
17/03/2025
Mercato del lavoro
Scienza
Biotecnologia
Farmaceutica
Salute
HIV, AIDS e malattie autoimmuni
Medicina - Varie
Contineum Therapeutics Announces Appointment of Diego Miralles, M.D. to Its Board of Directors
Fonte
Contineum Therapeutics, Inc.
Emittente
Business Wire
1.00
0

Recapiti

Social Media

Seguaci
0
Compatibilità
0